The 130th Annual Meeting of APHA |
Nancy X. T. Liu, MPH1, Daniel F. Alvarez, MD2, and Marcia Polansky, ScD1. (1) School of Public Health, MCP Hahnemann University, 1505 Race Street, Mail Stop 660, Philadelphia, PA 19102, 301-738-3640, nxl22@drexel.edu, (2) Department of Medicine, MCP Hahnemann University Hospital, 1427 Vine Street, 5th Floor, Philadelphia, PA 19102
Objective With the advent of highly active antiretroiviral therapy, HIV is rapidly becoming a manageable chronic disease with sustained decline in mortality and morbidity. As a result comorbidities due to hepatitis C have emerged to become one of the major causes of mortality among the HIV population. The objective of this study was to describe and analyze the sociodemographic characteristics, high-risk behavioral practices, psychiatric state, and clinical status of HIV individuals with and without hepatitis C. Methods A total of fifty-eight HIV patients of an inner city HIV/AIDS outpatient practice in Philadelphia, PA were enrolled in the study, 32 with HCV and 28 without HCV. Data were collected through a brief 15-minute interview and abstraction of medical chart for clinical and immunological data. Chi square tests were performed to determine any significant associations between hepatitis C seroprevalence and the outcome variables of interest. Logistic regression models were performed to characterize hepatitis C seroprevalence as a function of those variables found to be significant with Chi square tests. Results Of the sociodemographic that were examined, only age was significantly associated with hepatitis C seroprevalence (p=0.04). As for risk behaviors, IV drug use was strongly significant (p-value=0.000) and years of drug use was a predictor of HCV seroprevalence. Heavy alcohol use was associated with hepatitis C seroprevalence while social alcohol use was not (p=0.037 and 0.204 respectively). HIV viral load, CD4 count, and liver enzymes ALT and AST were not significantly associated with hepatitis C seroprevalence.
Learning Objectives:
Keywords: Hepatitis C, HIV/AIDS
Presenting author's disclosure statement:
I do not have any significant financial interest/arrangement or affiliation with any organization/institution whose products or services are being discussed in this session.